Strategies to maintain remission in high risk CD19 lymphoid malignancies

Name: Strategies to maintain remission in high risk CD19 lymphoid malignancies
Uploaded: 2013-06-19T10:00:00+00:00
Description: Dr Partow Kebriaei talks to ecancer at the 18th EHA Congress about her abstract on artificial antigen presenting cells that generate T cells expressing CD19-specific chimeric antigen receptor in order to prevent relapse in lymphoid malignancies.

18th Congress of EHA

Published: 19 Jun 2013

Rating:

Save

Dr Partow Kebriaei - MD Anderson Cancer Center, Houston, USA

Dr Partow Kebriaei talks to ecancer at the 18th EHA Congress about her abstract on artificial antigen presenting cells that generate T cells expressing CD19-specific chimeric antigen receptor in order to prevent relapse in lymphoid malignancies.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

28 Oct 2024

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

28 Oct 2024

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

28 Oct 2024

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

30 Sep 2024

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

30 Sep 2024

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$